{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:59:05Z","timestamp":1793228345654,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","award":["RP250322"],"award-info":[{"award-number":["RP250322"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020352","name":"Rexanna's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020813","name":"Troper Wojcicki Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020813","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtho.2026.01.007","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:42:39Z","timestamp":1768610559000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs"],"prefix":"10.1016","author":[{"given":"Monique B.","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Poteete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Diehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Almanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Soltys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sugio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurik","family":"Mutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeong","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shahrokh","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Oguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Weipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Kittler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.01.007_bib1","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib2","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib3","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130447","article-title":"Prevalence and clinicopathological characteristics of HER2 and BRAF mutation in Chinese patients with lung adenocarcinoma","volume":"10","author":"Shan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2026.01.007_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17425255.2016.1198317","article-title":"Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations","volume":"12","author":"Kourie","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jtho.2026.01.007_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.01.007_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1078-0432.CCR-05-0976","article-title":"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas","volume":"12","author":"Lee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.21037\/tlcr-20-559","article-title":"Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations","volume":"10","author":"Yang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.01.007_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.01.007_bib11","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, Phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2026.01.007_bib13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2026.01.007_bib15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.01.007_bib16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2026.01.007_bib17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 Exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib18","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","article-title":"Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer","volume":"28","author":"Sequist","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2019.02.017","article-title":"Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label Phase II NICHE trial of European thoracic oncology platform (ETOP)","volume":"14","author":"Dziadziuszko","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2015.01.013","article-title":"Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma","volume":"88","author":"De Gr\u00e8ve","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.01.007_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1078-0432.CCR-21-2936","article-title":"Pyrotinib in patients with HER2-amplified advanced non-small cell lung cancer: a prospective, multicenter, single-arm trial","volume":"28","author":"Song","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/annonc\/mdy542","article-title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib23","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II Study","volume":"38","author":"Zhou","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib24","doi-asserted-by":"crossref","first-page":"CT126","DOI":"10.1158\/1538-7445.AM2023-CT126","article-title":"Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and\/or HER2 mutation","volume":"83 (8_Supplement)","author":"Tan","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.01.007_bib26","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.01.007_bib27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study","volume":"43","author":"Heymach","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8598","article-title":"Safety and anti-tumor activity of BAY 2927088 in patients with HER2 -mutant NSCLC: results from an expansion cohort of the SOHO-01 phase I\/II study","volume":"42","author":"Girard","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2026.01.007_bib30","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-19-0419","article-title":"The Indenoisoquinoline TOP1 inhibitors selectively target homologous recombination-deficient and schlafen 11-positive cancer cells and synergize with Olaparib","volume":"25","author":"Marzi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.01.007_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1126\/science.8098549","article-title":"Multidrug resistance-associated protein: sequence correction","volume":"260","author":"Cole","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jtho.2026.01.007_bib33","first-page":"2594","article-title":"Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin","volume":"47","author":"Mirski","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.01.007_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4589","article-title":"A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components","volume":"12","author":"Nilsson","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2026.01.007_bib37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","article-title":"CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance","volume":"41","author":"Nilsson","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2026.01.007_bib38","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/0008-5472.CAN-21-1153","article-title":"Lentiviral-driven discovery of cancer drug resistance mutations","volume":"81","author":"Yenerall","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.01.007_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cas.15617","article-title":"TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations","volume":"114","author":"Oguchi","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2026.01.007_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2023.03.016","article-title":"Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, a multicenter, multicohort, open-label, phase 2 trial (Cohort 4)","volume":"18","author":"Cornelissen","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib43","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2026.01.007_bib44","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.18632\/oncotarget.6413","article-title":"Epigenetic inactivation of the putative DNA\/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs","volume":"7","author":"Nogales","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2026.01.007_bib45","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.01.007_bib46","first-page":"347","article-title":"NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer","volume":"8","author":"Molina","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.007_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41523-020-00201-9","article-title":"Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer","volume":"6","author":"Yi","year":"2020","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.jtho.2026.01.007_bib48","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtho.2026.01.007_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-016-0290-1","article-title":"EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer","volume":"9","author":"Wang","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib50","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jtho.2015.12.093","article-title":"Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer","volume":"11","author":"Song","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.007_bib51","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.1182\/blood-2022-167900","article-title":"Accurate detection of clinically actionable copy number variants in diverse hematological neoplasms by routine targeted sequencing: a comparative performance study","volume":"140","author":"Palomino Mosquera","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2026.01.007_bib52","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41467-023-36328-z","article-title":"Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer","volume":"14","author":"Hong","year":"2023","journal-title":"Nat Commun"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:38:37Z","timestamp":1772253517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S1556086426000079"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.01.007","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}